Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population

被引:0
|
作者
Decarreaux, Dorine [1 ,2 ,3 ]
Sevila, Julie [1 ]
Masse, Shirley [1 ]
Capai, Lisandru [1 ]
Fourie, Toscane [3 ]
Villarroel, Paola Mariela Saba [3 ]
Amroun, Abdennour [3 ]
Nurtop, Elif [3 ]
Vareille, Matthieu [1 ]
Blanchon, Thierry [2 ]
de Lamballerie, Xavier [3 ]
Charrel, Remi [3 ]
Falchi, Alessandra [1 ]
机构
[1] Univ Corse Pascal Paoli, Lab Virol, UR7310 Bioscope, F-20250 Corte, France
[2] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, INSERM, IPLESP, F-75012 Paris, France
[3] Aix Marseille Univ, Unite Virus Emergents, IHU Mediterranee Infect, INSERM U1207,IRD 190, F-13005 Marseille, France
关键词
COVID-19; seroconversion; long-lasting immunity; antibodies; vaccination; INFECTION; COVID-19;
D O I
10.3390/ijerph192215257
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background: Uncertainties remain regarding the nature and durability of the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Aim: This study investigated immunoglobulin G response and neutralizing activity to evaluate the mean antibody concentrations and response duration induced by each vaccination regimen in a French adult population. Methods: A study including blood sampling and questionnaires was carried out from November 2020 to July 2021 with three separate follow-up phases. Spike proteins and neutralizing antibodies were quantified using ELISA and a virus-neutralization test. Results: Overall, 295 participants were included. Seroprevalences were 11.5% (n = 34), 10.5% (n = 31), and 68.1% (n = 201) in phases 1, 2, and 3, respectively. Importantly, 5.8% (n = 17) of participants lost their natural antibodies. Antibody response of participants with only a prior infection was 88.2 BAU/mL, significantly lower than those vaccinated, which was 1909.3 BAU/mL (p = 0.04). Moreover, the antibody response of vaccinated participants with a prior infection was higher (3593.8 BAU/mL) than those vaccinated without prior infection (3402.9 BAU/mL) (p = 0.78). Vaccinated participants with or without prior infection had a higher seroneutralization rate (91.0%) than those unvaccinated with prior infection (65.0%). Conclusion: These results demonstrated that single infection does not confer effective protection against SARS-CoV-2.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies
    Vargas, Leonardo
    Valdivieso, Nicolas
    Tempio, Fabian
    Simon, Valeska
    Sauma, Daniela
    Valenzuela, Lucia
    Beltran, Caroll
    Castillo-Delgado, Loriana
    Contreras-Benavides, Ximena
    Acevedo, Monica L.
    Acevedo, Johanna
    Gonzalez, Rafael I.
    Valiente-Echeverria, Fernando
    Soto-Rifo, Ricardo
    Rosemblatt, Mario
    Lopez, Mercedes
    Osorio, Fabiola
    Bono, Maria Rosa
    BMC MEDICINE, 2022, 20 (01)
  • [22] Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies
    Leonardo Vargas
    Nicolás Valdivieso
    Fabián Tempio
    Valeska Simon
    Daniela Sauma
    Lucía Valenzuela
    Caroll Beltrán
    Loriana Castillo-Delgado
    Ximena Contreras-Benavides
    Mónica L. Acevedo
    Johanna Acevedo
    Rafael I. Gonzalez
    Fernando Valiente-Echeverría
    Ricardo Soto-Rifo
    Mario Rosemblatt
    Mercedes Lopez
    Fabiola Osorio
    María Rosa Bono
    BMC Medicine, 20
  • [23] Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies
    Lo Sasso, Bruna
    Agnello, Luisa
    Giglio, Rosaria Vincenza
    Scazzone, Concetta
    Massa, Davide
    Ciaccio, Anna Maria
    Gambino, Caterina Maria
    Vidali, Matteo
    Ciaccio, Marcello
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (04) : 1205 - 1211
  • [24] Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea
    Noh, Ji Yun
    Seo, Yu Bin
    Yoon, Jin Gu
    Seong, Hye
    Hyun, Hakjun
    Lee, Jacob
    Lee, Nuri
    Jung, Seri
    Park, Min-Jeong
    Song, Wonkeun
    Yoon, Jung
    Lim, Chae Seung
    Ryou, Jungsang
    Lee, Joo-Yeon
    Kim, Sung-Soon
    Cheong, Hee Jin
    Kim, Woo Joo
    Yoon, Soo-Young
    Song, Joon Young
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (33)
  • [25] PERSISTENCE OF ANTIBODIES AFTER SARS-COV-2 VACCINES IN HAEMODIALYSIS PATIENTS: A 6 MONTHS FOLLOW-UP
    Murt, Ahmet
    Altiparmak, Mehmet Riza
    Pekpak, Meltem
    Ataman, Rezzan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I667 - I667
  • [26] Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies
    Bruna Lo Sasso
    Luisa Agnello
    Rosaria Vincenza Giglio
    Concetta Scazzone
    Davide Massa
    Anna Maria Ciaccio
    Caterina Maria Gambino
    Matteo Vidali
    Marcello Ciaccio
    Clinical and Experimental Medicine, 2023, 23 : 1205 - 1211
  • [27] ANTI-SARS-COV-2 ANTIBODIES IN IMMUNOGLOBULIN PRODUCTS (COVIG)
    Tedja, Anatasha
    Acquarola, Nick
    Gibbs, Tristan
    Mallon, Dominic
    Salman, Sam
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 30 - 30
  • [28] High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers
    Gelanew, Tesfaye
    Seyoum, Berhanu
    Mulu, Andargachew
    Mihret, Adane
    Abebe, Markos
    Wassie, Liya
    Gelaw, Baye
    Sorsa, Abebe
    Merid, Yared
    Muchie, Yilkal
    Teklemariam, Zelalem
    Tesfaye, Bezalem
    Osman, Mahlet
    Jebessa, Gutema
    Atinafu, Abay
    Hailu, Tsegaye
    Habte, Antenehe
    Kenea, Dagaga
    Gadisa, Anteneh
    Admasu, Desalegn
    Tesfaye, Emnet
    Bates, Timothy A.
    Bulcha, Jote Tafese
    Tschopp, Rea
    Tsehay, Dareskedar
    Mullholand, Kim
    Howe, Rawleigh
    Genetu, Abebe
    Tafesse, Fikadu G.
    Abdissa, Alemseged
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [29] High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers
    Tesfaye Gelanew
    Berhanu Seyoum
    Andargachew Mulu
    Adane Mihret
    Markos Abebe
    Liya Wassie
    Baye Gelaw
    Abebe Sorsa
    Yared Merid
    Yilkal Muchie
    Zelalem Teklemariam
    Bezalem Tesfaye
    Mahlet Osman
    Gutema Jebessa
    Abay Atinafu
    Tsegaye Hailu
    Antenehe Habte
    Dagaga Kenea
    Anteneh Gadisa
    Desalegn Admasu
    Emnet Tesfaye
    Timothy A. Bates
    Jote Tafese Bulcha
    Rea Tschopp
    Dareskedar Tsehay
    Kim Mullholand
    Rawleigh Howe
    Abebe Genetu
    Fikadu G. Tafesse
    Alemseged Abdissa
    BMC Infectious Diseases, 22
  • [30] Immunoassays for anti-SARS-CoV-2 antibodies: recent insights
    Van Elslande, Jan
    Andre, Emmanuel
    Van Ranst, Marc
    Lagrou, Katrien
    Vermeersch, Pieter
    LANCET INFECTIOUS DISEASES, 2021, 21 (05): : E118 - E118